Clinical trials: Age Related Maculopathy
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Eye Diseases, Macular Degeneration, Wet
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces.
- Conditions
- Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
- Trial name
- TIGER (NCT04663750)
- Testing
- Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12, subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Where
- 42 sites in Germany, Ireland and 5 more
- Volunteers
- 210 people
- Sponsor
- King's College Hospital NHS Trust
Age-Related Macular Degeneration, Diabetic Retinopathy
Retinal Imaging Using NOTAL-OCT
Comparison between retinal measurements, done by the Notal-OCT imaging and a commercial OCT (Optical Coherence Tomography)
- Trial name
- NCT03374020
- Testing
- Notal OCT
- Volunteers
- 33 people
- Sponsor
- Notal Vision Ltd.
Uveitis, Iritis
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
Retinal optical coherence tomography (OCT) is an established technology which enables a detailed cross-sectional visualization of the retinal micro-anatomy, and an objective measurement of its thickness in-vivo.
- Conditions
- Uveitis, Iritis, Iridocyclitis, Anterior Uveitis
- Trial name
- NCT00476593
- Testing
- Diclofenac, Dexamethasone
- Where
- 2 sites in Norway
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Age-related Macular Degeneration, Aging
Functionally Validated Structural Endpoints for Early AMD
Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD).
- Trial name
- ALSTAR2 (NCT04112667)
- Testing
- Normal Macular Health, Early Macular Degeneration, Young Normals
- Where
- United States
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Cynthia Owsley
wetAMD, Age Related Macular Degeneration
Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration
Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration.
- Trial name
- NCT07607561
- Testing
- SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TID
- Volunteers
- 50 people
- Sponsor
- SCAI Therapeutics
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
Neovascular Age-related Macular Degeneration
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients.
- Trial name
- nAMD (NCT05461339)
- Testing
- TAB014 Monoclonal Antibody Injection, Ranibizumab Injection [Lucentis]
- Where
- 56 sites in China
- Volunteers
- 488 people
- Sponsor
- BioDlink Biopharm Co., Ltd.
Wet Age Related Macular Degeneration
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).
- Trial name
- TWEYES (NCT01986907)
- Testing
- ranibizumab
- Where
- 101 sites in Italy
- Volunteers
- 1,049 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.
- Trial name
- SHIFT-2 (NCT02002377)
- Testing
- Aflibercept
- Where
- 9 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Unity Health Toronto
Age-Related Macular Degeneration, Geographic Atrophy
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years.
- Trial name
- APENNINES (NCT06351657)
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Elderly French Population, Age-related Macular Degeneration
Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors
Age-related Macular Degeneration (AMD) is the most cause of blindness in the industrialised countries. There are few epidemiological studies on the incidence of this disease.
- Trial name
- ECLAIR (NCT01918553)
- Testing
- clinical parameters, visual acuity exams, retinophotography
- Where
- France
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Age Related Macular Degeneration, Intravitreal Injections
Aflibercept in Recurrent or Persistent CNV
Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in the central retina.
- Conditions
- Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema
- Trial name
- OPHTH-010915 (NCT02669953)
- Testing
- Aflibercept
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Medical University of Vienna
Macular Degeneration
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
- Trial name
- NCT00612456
- Testing
- Pazopanib
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Wet Age-related Macular Degeneration (wAMD)
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
- Trial name
- HEIRLOOM (NCT07129239)
- Testing
- Maintenance
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Clinique de Retine de l'est
Macular Degeneration
A Single-Center Pilot Study to Assess Macular Function
This study seeks to evaluate a novel endpoint for future dry AMD clinical trials.
- Trial name
- NCT01204541
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye.
- Trial name
- NCT06970665
- Testing
- avacincaptad pegol
- Where
- 11 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc
Pain
Intravitreal Injection Site and Perceived Pain
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Trial name
- NCT05640895
- Testing
- Intravitreal injection site
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Dry Age-related Macular Degeneration, Macular Degeneration
GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Trial name
- NCT03894020
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Gyroscope Therapeutics Limited
Macular Degeneration
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
In this clinical study researchers want to gain a deeper understanding of treatment consistence under real world conditions over the course of 24 months of Aflibercept injections into the eye for patients suffering from abnormal…
- Trial name
- ANDROMEDA (NCT03714308)
- Testing
- Ivt. Aflibercept (Eylea, BAY86-5321)
- Where
- Germany
- Volunteers
- 554 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.